There is evidence for gender differences in the treatment and outcome of acute myocardial infarction (AMI). However, little data exist about these differences in patients from the Arab Middle East. Therefore, we studied the influence of patient gender on the presentation, the use of thrombolytic therapy, and in-hospital mortality after AMI in Kuwaiti nationals. This is a retrospective study of all consecutive Kuwaiti patients admitted to the coronary care unit of a university hospital with the diagnosis of AMI between June 1994 and May 1997. A total of 89 women and 267 men were included. Women were older than men and had significantly higher rates of diabetes (72% vs 46%), hypertension (58% vs 33%) and hypercholesterolemia (80% vs 53%). Women were less likely to receive thrombolytic therapy (40% vs 62%, p=0.001). Fewer women were eligible for thrombolytic therapy (50% vs 66%, p<0.05). Of those who were eligible for thrombolysis there was no sex difference in receiving such treatment. The in-hospital mortality among women younger than 70 years was 2.5 times higher than among men in the same age group; while there was no difference in mortality between women and men aged 70 years and older. We conclude that women and men with AMI have different clinical characteristics and outcomes following AMI. There was no gender bias for the use of thrombolytic therapy. The higher in-hospital mortality in younger women, i.e. less than 70 years, compared to younger men, indicates that younger women with AMI should be considered as a high-risk group. (Jpn Heart J 2001; 42: 669-676) Key words: Myocardial infarction, Gender, Thrombolytic therapy, Outcome, Middle East HEART disease is a leading cause of death in Kuwait. In 1995, coronary artery disease was responsible for 15.4% of all deaths among Kuwaitis and 23.6% of all deaths among expatriates. 1) Although coronary artery disease is more prevalent in men, it is the leading cause of death in women as in men. Several studies have assessed sex-based differences in treatment and mortality following AMI. It has From the
been shown that women were less likely to receive medical treatment and invasive cardiac procedures. [2] [3] [4] [5] [6] [7] [8] [9] Most studies have reported higher mortality among women, [10] [11] [12] [13] [14] [15] [16] [17] while others have reported similar mortality rates among men and women. 2, [18] [19] [20] [21] It is unclear whether the noticed gender differences in treatment and outcome following AMI are related to differences in baseline clinical characteristics, gender-bias in treatment administration, or to pathophysiological differences between women and men.
Although there are many studies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] of gender differences following AMI, to our knowledge, no such studies have beer reported from the Arab Middle East. The Kuwaiti population originates from an Arab ethnic background. Our patients are young and have a high prevalence of diabetes. 22 ) Therefore, we conducted this study to assess the influence of gender on the presentation, use of thrombolytic therapy, and in-hospital mortality after AMI in Kuwaiti nationals.
PATIENTS AND METHODS
The study was conducted at the coronary care unit (CCU) of Mubarak AlKabeer Hospital, a 476-bed university hospital. All Kuwaiti patients who were discharged from, or died in, the CCU with the final diagnosis of AMI during a 3-year period between June 1994 and May 1997 were included in the study. If a patient was admitted more than once with a diagnosis of AMI, only the first admission was included in the analysis.
A structured data collection form, including detailed information on medical history, physical examination, ECG, cardiac enzymes, lipid profile, blood sugar, admission and discharge diagnoses, thrombolytic therapy execution, and in-hospital course was completed from the patients' records.
The diagnosis of AMI was based on any two of the following three criteria: ischemic type chest pain, diagnostic serial ECG changes and doubling of creatine kinase with an at least 6% MB fraction. Patients were considered eligible for thrombolytic therapy if they met all of the following criteria: (1) presentation within 12 hours of symptom onset; (2) ST-segment elevation >0.1 mV in two or more limb leads, or >0.2 mV in two or more contiguous precordial leads; or left bundle branch block (LBBB); and (3) absence of contraindications to thrombolytic therapy.
Patients with any of the following conditions were considered as having absolute contraindication to thrombolytic therapy: acute internal bleeding, suspected aortic dissection, blood pressure >200/120 mmHg not responding to treatment, non-hemorrhagic stroke within 6 months, history of hemorrhagic stroke, known intra-cranial neoplasm or arterio-venous malformations, head trauma or Vol 42 No 6 surgery within 2 months, and a known bleeding disorder. Patients received either tissue plasminogen activator or streptokinase, as thrombolytic therapy.
The observed thrombolysis rate is the actual rate of thrombolysis. The shortfall is the percentage of patients who were eligible for thrombolytic treatment, but did not receive it. Non-diagnostic ECG meant the absence of ST-segment elevation or LBBB on presentation. Statistical methods: Student's independent t-test was used to determine the significant differences between men and women in cases of continuous variables such as age. The significance of gender differences was tested using the standard tests of proportions for all the variables that were categorical. 18) Analyses were carried out using SPSS and INSTAT and summary results were tabulated. A probability level >0.05 was taken as an indication of no significant difference.
RESULTS

Baseline clinical characteristics of patients:
During the study period, 89 women and 267 men were admitted with AMI. Women were older than men, with mean ages of 61 and 56 years, respectively (p<0.0001). Women were more likely to have hypertension, diabetes, elevated cholesterol levels and a history of congestive heart failure ( Table I) . They were less likely to be smokers. Fewer women than men presented with ST-segment elevation, but this was not statistically significant (52% vs 67%, p=0.06). Fewer women than men presented to the hospital within 6 hours of the onset of chest pain (50% vs 66%, p=0.04) ( Table I) . Use of thrombolytic therapy: Overall, 228 (64%) of the 356 patients were eligible for thrombolytic treatment. The majority (78%) of the eligible patients received thrombolytic treatment. Women were less likely than men to be eligible for thrombolytic therapy (54% vs 67%, p=0.01). However, there was no significant difference in thrombolysis rate between eligible women and men (Table II) . In-Hospital mortality: The overall in-hospital mortality rate was higher for women than for men (21% vs. 11%, respectively; p=0.02). The in-hospital mortality rate in both women and men increased as a function of age (Figuee). The inhospital mortality rate among women younger than 70 years was higher compared to that of men of the same age group (16% vs 6%, respectively; p=0.008). There was no difference in the in-hospital mortality rate among women and men 70 years and older (Figure) . (20) 34 (71) 14 (29) NS NS Figure 1 . In-hospital mortality rates of women and men according to the two age groups. * Indicates p=0.008 for women vs men <70.
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Clinical characteristics of patients according to age: Comparison of the baseline clinical characteristics between women and men according to two age groups, less than 70 years and equal to or above 70 years, showed significant age-related differences (Table III) . Younger women (below 70 years) were more likely than younger men to have hypertension (56% vs 35%, p=0.002), hypercholesterolemia (83% vs 60%, p<0.01) and a history of congestive heart failure (6% vs 1%, p=0.03), but no sex-based differences were present in the older age group. Younger women had a significantly higher rate of diabetes than younger men (71% vs 46%, p= 0.0030) ( Table III) . Younger women were more likely to have a higher Killip class on admission (23% vs 13%, p<0.05) and were less likely to present with an ST-segment elevation infarction than younger men (53% vs.68%, p=0.02). Again, these differences were not present in the at older agegroup. Fewer younger women presented to the hospital within 6 hours of the onset of chest pain compared to men of the same age group (58% vs 75%, p<0.05), but there was no difference in duration from chest pain to hospital presentation in the older age group (Table III) . 
DISCUSSION
Multiple studies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] have shown that women with AMI tend to be older than men and are more likely to have a history of hypertension, diabetes, hypercholesetrolemia and congestive heart failure. Women on the other hand are less likely to be smokers. Our study confirms these findings but shows a very high rate of diabetes among our patients in comparison to the other studies. [10] [11] [12] [13] [18] [19] Fewer women were eligible for thrombolytic therapy than men. Of those who were eligible, there was no difference in the observed thrombolysis rate between women and men. Differences in eligibility for thrombolytic therapy can affect the observed thrombolysis rates. We could overcome this difficulty by comparing women and men who were considered clearly eligible for this treatment.
Another important finding is that 78% of all eligible patients received thrombolytic therapy. Although this is a high rate of thrombolysis compared to other studies, 2, [24] [25] it still implies that we are failing to administer this life-saving treatment to around 20% of the patients who would benefit from it.
Consistent with previous studies, [10] [11] [12] [13] [14] [15] [16] [17] we found that women had a higher risk of early death after AMI than men. The fact that women were older than men in our study population can explain this finding. However, further data analysis showed that this gender difference in mortality was significant only among younger patients and was no longer present among women and men 70 years or older. This increased mortality among younger women has several possible explanations. Fewer women than men received life-saving thrombolytic therapy. We did not study the use of other effective treatments like aspirin, beta-blockers, and the use of coronary angiography and subsequent revascularization. However, It has been shown that women were less likely to receive medical treatment and invasive cardiac procedures. [2] [3] [4] [5] [6] [7] [8] [9] 21) Another possible explanation for this increased mortality is that younger women had more risk factors for coronary artery disease than did younger men and were more likely to have a history of congestive heart failure and a higher Killip class on presentation. Of special importance is a significantly higher risk of diabetes in women, which has been shown to be an independent poor prognostic factor in patients with AMI [26] [27] [28] Other possible explanations include sex differences in the pathophysiology of coronary artery disease 29) or differences in thrombotic and fibrinolytic activity. 30) Finally, population based registries of AMI suggest that the differences observed in case fatality between hospitalised women and men are balanced by a larger pre-hospital case fatality rate in men. 20, 23) Our study has some limitations. This was a retrospective study, however, all consecutive cases of AMI were included which makes the data valuable for doc-Vol 42 No 6 umenting patient demographics, practice patterns and outcome of patients. The sample size is relatively small, however, it represents a three-year case load to a large hospital.
We conclude that women with AMI have different baseline clinical characteristics as compared to men. Women received thrombolytic therapy less frequently than men because they were less often eligible for this treatment. We found no gender bias in administering thrombolytic therapy among our patients. However, there is room for improving compliance with the guidelines for administering life-saving thrombolytic treatment in both sexes. The higher in-hospital mortality in younger women compared to younger men indicates that younger women with AMI should be considered a high-risk group.
